


To achieve capital growth and income from a portfolio of predominantly UK equities
| Name | % Net Assets | 
|---|---|
| Royal Dutch Shell PLC | 8.7% | 
| GlaxoSmithKline PLC | 6.3% | 
| Vodafone Group PLC | 5.9% | 
| BG Group PLC | 4.4% | 
| AstraZeneca PLC | 4.4% | 
| British American Tobacco PLC | 4.0% | 
| Unilever PLC | 3.1% | 
| Cadbury PLC | 2.8% | 
| BP PLC | 2.8% | 
| Centrica PLC | 2.7% | 
| Key | % Net Assets | 
|---|---|
| 8.7% | |
| 6.3% | |
| 5.9% | |
| 4.4% | |
| 74.7% | 
| Date | 02-Oct-2023 | 
|---|---|
| NAV | 313.04p | 
| Currency | GBP | 
| Change | -3.66p | 
| % | -1.16% | 
| YTD change | 313.04p | 
| YTD % | n/a | 
| Fund Inception | 01/05/1985 | 
|---|---|
| Fund Manager | Glen Pratt | 
| TER | 1.04 (30-Dec-2011) | 
| Minimum Investment | |
|---|---|
| Initial | n/a | 
| Additional | n/a | 
| Savings | n/a | 
| Charges | |
|---|---|
| Initial | 4.00% | 
| Annual Mang't | 1.00% | 
| Exit | n/a | 
| Name | % | 
|---|---|
| Standard deviation | 0.02 | 
| Sharpe ratio | 0.06 | 
You are here: research